ArticleAmerican heart journal2026
Cardiometabolic health of low- and higher-income adults in the United States, 2009-2023.
Article in American heart journal, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
7 authors.
Funding
Abstract
backgroundCardiometabolic risk factors are major contributors to premature mortality in the United States. Little is known about recent changes in the cardiometabolic health of US adults by income level, particularly after the COVID-19 pandemic.
objectiveTo assess changes in the cardiometabolic health of US adults from 2009 to August 2023 by income level, and to evaluate pandemic-related shifts.
methodsWe conducted a serial cross-sectional analysis of National Health and Nutrition Examination Survey participants aged ≥ 18 years (2009-2010 to August 2021-August 2023). Low-income was defined as ≤ 200% of the federal poverty level. We evaluated changes in the age- and sex-adjusted prevalence, treatment, and control of hypertension, diabetes, and high cholesterol, and the prevalence of obesity and smoking, among low- and higher-income adults. Linear regression models estimated pandemic-associated shifts.
resultsAmong 62,108 adults (mean age 46.3 years; 51.7% female), the prevalence of hypertension or high cholesterol did not change in either income group. Obesity prevalence rose among low-income adults (37.3% to 42.1%; absolute change +4.8 pp [95% CI, 1.1, 8.5]). Diabetes prevalence increased in both groups (low-income: +5.1 pp [1.4, 8.8]; higher-income: +2.5 pp [0.7, 4.3]), but remained higher among low-income adults (17.6% vs 12.4%; absolute difference +5.2 pp [1.6, 8.8]). While diabetes treatment did not change, an income-related gap in diabetes control emerged: by August 2021-August 2023, 43.0% of low-income adults achieved glycemic control compared to 52.8% of higher-income adults (absolute difference -9.8 pp [-17.5, -2.1]), coinciding with a greater-than-expected decline in diabetes control among low-income adults in the wake of the pandemic (level shift -8.7 pp [-16.7, -0.6]). The income-related gap in hypertension treatment in 2009-2010 had closed by August 2021-August 2023, following a greater-than-expected increase in treatment among low-income adults after the pandemic (level shift +7.8 pp [1.8, 13.8]). High cholesterol treatment and control improved in both groups, with no income-related differences. Smoking declined for both low-income (30.2% to 22.8%, absolute change -7.4 pp [-12.0, -2.8]) and higher-income (15.0% to 10.3%, absolute change -4.7 pp [-7.1, -2.3]) adults, but remained more than two-fold higher in the low-income group.
conclusionsBetween 2009 and August 2023, there was no improvement in the prevalence of hypertension or high cholesterol. Obesity and diabetes prevalence rose among low-income adults and a new income-related gap in diabetes control emerged, coinciding with a greater-than-expected decline in glycemic control among low-income adults after the pandemic. Targeted efforts are needed to improve risk factor prevention, strengthen glycemic control in low-income populations, and address persistent income-related disparities in cardiometabolic health.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.